ArticleJapanese journal of radiology2026
Characteristic contrast-enhanced MRI findings of nodular fasciitis and their chronological change.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify characteristic contrast-enhanced MRI features of nodular fasciitis that aid in differentiating it from malignant tumors and to evaluate their chronological changes. MATERIALS AND
methodsWe analyzed 62 histologically confirmed nodular fasciitis lesions from 61 patients. All patients underwent T2-weighted and post-contrast MRI. Non-enhancing patterns were categorized as follows: type 1 (homogeneous enhancement), type 2 (central non-enhancement), type 3 (heterogeneous non-enhancement), and type 4 (predominantly non-enhancing). Type 4 was subdivided into type 4a (predominantly non-enhancing with minimal peripheral enhancement) and type 4b (completely non-enhancing with perilesional enhancement). MRI findings from 50 malignant tumors served as controls.
resultsThe initial MRI patterns included type 1 (n = 24, 39%), type 2 (n = 17, 27%), type 3 (n = 9, 15%), and type 4 (n = 12, 19%). Among the 12 type 4 lesions, 8 exhibited type 4b. Three additional lesions evolved into type 4b, totaling 11 (17%) of the 62. A follow-up MRI was performed in 5 type 4b lesions; 4 demonstrated changes to other types, although without a consistent transformation pattern. Type 4b lesions were absent in the malignant control group.
conclusionIn this cohort, type 4b was observed in nodular fasciitis and not in the malignant controls evaluated; specificity beyond this control spectrum remains unknown and requires external validation. The temporal evolution from type 4b to other patterns was variable, potentially explaining the previously reported heterogeneity in MRI findings. Follow-up imaging may help explain the variability in reported MRI appearances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.